Show simple item record

dc.contributor.authorValpione, Sara
dc.contributor.authorCarlino, M
dc.contributor.authorMangana, J
dc.contributor.authorMooradian, M
dc.contributor.authorMcArthur, G
dc.contributor.authorSchadendorf, D
dc.contributor.authorHauschild, A
dc.contributor.authorMenzies, A
dc.contributor.authorArance, A
dc.contributor.authorAscierto, P
dc.contributor.authorDi Giacomo, A
dc.contributor.authorde Rosa, F
dc.contributor.authorLarkin, J
dc.contributor.authorPark, J
dc.contributor.authorGoldinger, S
dc.contributor.authorSullivan, R
dc.contributor.authorXu, W
dc.contributor.authorLivingstone, E
dc.contributor.authorWeichenthal, M
dc.contributor.authorRai, R
dc.contributor.authorGaba, L
dc.contributor.authorLong, G
dc.contributor.authorLorigan, Paul C
dc.date.accessioned2018-02-08T13:27:02Z
dc.date.available2018-02-08T13:27:02Z
dc.date.issued2018-01-19
dc.identifier.citationRechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. 2018, 91:116-124 Eur J Canceren
dc.identifier.issn1879-0852
dc.identifier.pmid29360604
dc.identifier.doi10.1016/j.ejca.2017.12.007
dc.identifier.urihttp://hdl.handle.net/10541/620817
dc.description.abstractMost metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer (Oxford, England : 1990)en
dc.titleRechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.en
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, and University of Manchester, Manchester, UKen
dc.identifier.journalEuropean Journal of Canceren
refterms.dateFOA2018-12-17T15:13:42Z
html.description.abstractMost metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy.


Files in this item

Thumbnail
Name:
PIIS0959804917314867.pdf
Size:
1.014Mb
Format:
PDF
Description:
Open access full text article

This item appears in the following Collection(s)

Show simple item record